Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 27;15(11):2948.
doi: 10.3390/cancers15112948.

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences

Sonia Morè  1 , Massimo Offidani  1 , Laura Corvatta  2 , Maria Teresa Petrucci  3 , Francesca Fazio  3
Affiliations
Review

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences

Sonia Morè et al. Cancers (Basel). .

Abstract

Despite the recent approval of novel immunotherapies, such as immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multiple Myeloma (MM) remains incurable, and the acquisition of triple-refractoriness leads to really dismal outcomes in even earlier lines of therapy. More recently, innovative therapeutic strategies targeting B cell maturation antigen (BCMA), highly expressed on the plasma cell surface, are drawing different future landscapes in terms of effectiveness and outcomes. Belantamab Mafodotin, a first-in-class anti-BCMA antibody-drug conjugate, demonstrated good efficacy and safety profile in triple-refractory patients in the phase 2 DREAMM-2 trial, and it was approved for the treatment of MM triple-exposed patients with >4 prior lines of therapy. Here, starting from Belantamab Mafodotin clinical trials and also exploring combination studies and different schedules in order to improve its efficacy and toxicity, we focused on real-life experiences all over the world, which have confirmed clinical trial data and encourage further Belantamab Mafodotin investigations.

Keywords: antibody–drug conjugate; belantamab mafodotin; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

S.M.: Honoraria from Amgen, Janssen. L.C.: Honoraria from Celgene, Janssen, Amgen; M.O.: Honoraria from and Advisor for AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Roche, Sanofi, Takeda; M.T.P.: Honoraria from Janssen-Cilag, Celgene-BMS, Amgen, Sanofi, GSK, Takeda; Advisor for Janssen-Cilag, Celgene-BMS, Amgen, Sanofi, GSK, Takeda, Roche, Karyopharm; Support for attending meetings and/or travel from Janssen-Cilag, Celgene-BMS, Amgen, Sanofi, Takeda. F.F.: Advisor for Takeda, Sanofi, Honoraria from GSK, Janssen, Amgen.

Figures

Figure 1
Figure 1
Mechanism of action of belantamab mafodotin. After binding to BCMA on plasmacell, ADC is degraded in the lysosome with release of MMAF that leads to G2/M arrest and caspase 3 dependent apoptosis. Belamaf exerts antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abramson H.N. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int. J. Mol. Sci. 2018;19:3924. doi: 10.3390/ijms19123924. - DOI - PMC - PubMed
    1. Bonello F., Mina R., Boccadoro M., Gay F. Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers. 2020;12:15. doi: 10.3390/cancers12010015. - DOI - PMC - PubMed
    1. Wudhikarn K., Wills B., Lesokhin A.M. Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action. Best Pract. Res. Clin. Haematol. 2020;33:101143. doi: 10.1016/j.beha.2020.101143. - DOI - PMC - PubMed
    1. Kumar S.K., Therneau T.M., Gertz M.A., Lacy M.Q., Dispenzieri A., Rajkumar S.V., Fonseca R., Witzig T.E., Lust J.A., Larson D.R., et al. Clinical Course of Patients with Relapsed Multiple Myeloma. Mayo Clin. Proc. 2004;79:867–874. doi: 10.4065/79.7.867. - DOI - PubMed
    1. Mikkilineni L., Kochenderfer J.N. Chimeric Antigen Receptor T-Cell Therapies for Multiple Myeloma. Blood. 2017;130:2594–2602. doi: 10.1182/blood-2017-06-793869. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.